Financial result for the quarter and year ended March 31, 2026
FCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 21.6 pts more than Nifty Microcap 250 and 21.9 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fineotex Chemical reported strong consolidated performance for FY 2025-26 with revenue growing 44.79% to Rs. 772.23 Crores and PAT increasing 14.50% to Rs. 125.01 Crores. Q4 showed exceptional growth with revenue up 161.91% YoY to Rs. 313.73 Crores and PAT up 117.56% to Rs. 43.80 Crores. However, standalone revenue declined from Rs. 439.22 Crores to Rs. 396.88 Crores, indicating subsidiaries drove the growth. The company declared total dividend of Rs. 14.99 Crores vs Rs. 9.17 Crores previous year. Auditors issued unqualified reports with no concerns. Key concern is negative operating cash flow of Rs. 7,310.92 lakhs on standalone basis (vs +Rs. 5,810.01 lakhs prior year) and trade receivables nearly tripled to Rs. 29,028.61 lakhs, suggesting working capital stress. Company executed a 4:1 bonus issue and stock split during the year.
Strong revenue and profit growth on consolidated basis is positive for the stock, but negative operating cash flow and sharp rise in receivables warrant caution. The bonus issue increased share count significantly.